What's Happening?
ADC Therapeutics has experienced a significant drop in its share price following the revelation of patient deaths in a clinical trial involving its drug Zynlonta. The phase 3 LOTIS-5 trial, which included 440 patients with relapsed or refractory diffuse
large B-cell lymphoma, reported 27 deaths in the study arm compared to nine in the control group. Zynlonta was tested in combination with Roche’s monoclonal antibody Rituxan, while the control group received Rituxan with chemotherapies gemcitabine and oxaliplatin. Most deaths occurred in patients aged 75 and older, primarily due to infections. Despite achieving its primary endpoint of progression-free survival, the trial's adverse outcomes have overshadowed these results, leading to a 52% drop in ADC's share price.
Why It's Important?
The trial results are crucial as they impact ADC Therapeutics' market position and financial stability. Zynlonta is the company's only commercial product, and its success is vital for ADC's future. The trial's negative outcomes could affect the drug's approval process and its potential market expansion from third-line to second-line treatment. The financial implications are significant, with the company's share price plummeting and potential investor confidence shaken. This development also raises broader concerns about the safety and efficacy of antibody-drug conjugates in treating aggressive lymphomas, potentially influencing future research and regulatory scrutiny in this field.
What's Next?
ADC Therapeutics plans to meet with the FDA in August to discuss the trial results and intends to submit for approval in the fourth quarter of the year. The company is also conducting the LOTIS-7 trial, exploring Zynlonta in combination with Roche’s bispecific antibody Columvi for B-cell non-Hodgkin lymphoma. The outcomes of these discussions and trials will be pivotal in determining Zynlonta's future in the market and ADC's strategic direction. Stakeholders, including investors and healthcare professionals, will closely monitor these developments for potential impacts on treatment protocols and market dynamics.
